The UK and US have forged a major trade agreement that will guarantee zero tariffs on British pharmaceutical shipments being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these crucial exports will remain at nothing for a period of the next three years.
This agreement follows previous statements to dramatically increase tariffs on patented drug imports, with increases mentioned as high as double the cost.
"This arrangement with the Britain strengthens the international landscape for new treatments and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release noted.
Commercial Importance
Medicines are one of the the United Kingdom's largest export categories to the United States, which is by far the primary destination for major UK drugmakers.
Statistics show that in the 12 months leading up to last September, the UK sold drugs worth over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that span.
"This agreement secures work, stimulates funding and facilitates the UK to establish itself as a worldwide center for life sciences," a minister remarked.
Detailed British Pledges
The pact includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to double overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, refunds topped 20%.
Industry Background
This agreement comes amid a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and approval rates.
This friction were intensified by assertions that American patients were charged significantly more for the equivalent treatments than patients in the other developed nations.
Recently, several large drug company projects in the UK have been halted or cancelled, while major investments have been pledged toward American operations.
A senior figure stated that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the last ten years.
